Judith Currier

Professor

University of California, Los Angeles

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Judith Currier is a Professor at the University of California, Los Angeles. Her research focuses on HIV-related health issues, particularly the cardiovascular effects of antiretroviral therapies and the immune response to viral infections such as SARS-CoV-2. Recent publications include studies on the impacts of statin treatment in HIV patients and the clinical consequences of delaying long-acting antiretroviral therapy.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Carlos Malvestutto

Associate Professor

The Ohio State University Wexner Medical Center

UNITED STATES

View details

Gerald Bloomfield

Duke University

UNITED STATES

View details

Samir Gupta

Professor of Medicine

Indiana University School of Medicine

UNITED STATES

View details

Edgar Overton

The University of Alabama

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Judith Currier

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV

Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort

Clinical Consequences of Delaying Implementation of Long-Acting Antiretroviral Therapy for People With HIV and Persistent Viremia in the United States

Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV

Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2

Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention

SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19

ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients

Immune Status and SARS-CoV-2 Viral Dynamics

Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial

Collaborators (4)

Carlos Malvestutto

Gerald Bloomfield

Samir Gupta

Edgar Overton

Make your next move.